<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04685720</url>
  </required_header>
  <id_info>
    <org_study_id>BA_NTM_AU_01.01</org_study_id>
    <nct_id>NCT04685720</nct_id>
  </id_info>
  <brief_title>A Pilot Study to Assess the Effect of Intermittent iNO on the Treatment of NTM Lung Infection in CF and Non-CF Patients</brief_title>
  <official_title>A Pilot Study to Assess the Effect of Intermittent Inhaled Nitric Oxide on the Treatment of Nontuberculous Mycobacteria (NTM) Lung Infection in Cystic Fibrosis and Non-Cystic Fibrosis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beyond Air Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beyond Air Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this open-label, multicenter, non-randomized, pilot study is to assess the&#xD;
      safety of high dose intermittent iNO for treatment of NTM infection in CF and non-CF&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include 20 patients from up to four clinical sites in Australia. The overall&#xD;
      treatment plan includes 2 weeks of inhalation treatments (intensive phase) of iNO four times&#xD;
      per day at 4.5-hour intervals followed by 10 weeks of inhalation treatments (maintenance&#xD;
      phase) at the maximum tolerated dose (a maximum of 250 ppm NO) inhaled twice daily.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 7, 2020</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-Emergent SAEs</measure>
    <time_frame>Day 1 to Day 84</time_frame>
    <description>The primary endpoint of the study is the number of patients with treatment-emergent SAEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in NTM bacterial load from baseline to Day 174</measure>
    <time_frame>Day 1 to Day 174</time_frame>
    <description>Changes in NTM bacterial load will be assessed by sputum culture in liquid and solid media.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with culture conversion at Day 174</measure>
    <time_frame>Day 1 to Day 174</time_frame>
    <description>NTM culture conversion will be defined as having at least three consecutive negative NTM cultures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in quality of life assessed by CFQ-R for or QOL-B with NTM module</measure>
    <time_frame>Day 1 to Day 174</time_frame>
    <description>Changes in quality of life assessed by Cystic Fibrosis Questionnaire Revised [CFQ R] for CF patients or Quality of Life Questionnaire-Bronchiectasis [QOL-B] with NTM module for non-CF patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in FEV1 from baseline to Day 174</measure>
    <time_frame>Day 1 to Day 174</time_frame>
    <description>Respiratory function will be assessed by spirometry including FEV1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in activity tracker data as assessed by changes in distance from baseline to Day 174.</measure>
    <time_frame>Day 1 to Day 174</time_frame>
    <description>Patients will collect activity tracker data from 2 weeks before treatment and from Day 1 to Day 174.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 6 Minute Walking Test</measure>
    <time_frame>Day 1 to Day 84</time_frame>
    <description>Change in 6 Minute Walking Test will be assessed by changes in distance between baseline and Day 84</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Non-Tuberculous Mycobacterial Pneumonia</condition>
  <condition>Cystic Fibrosis</condition>
  <condition>Mycobacterial Pneumonia</condition>
  <condition>Mycobacterium Abscessus Infection</condition>
  <condition>Mycobacterium Avium Complex</condition>
  <arm_group>
    <arm_group_label>Inhaled NO delivered using LungFit</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled Nitric Oxide in doses up to 250 ppm</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LungFit</intervention_name>
    <description>LungFit for NTM is an experimental device that produces Nitric Oxide from the ambient air.</description>
    <arm_group_label>Inhaled NO delivered using LungFit</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects diagnosed with refractory NTM (MAC or MAbs) pulmonary infection&#xD;
&#xD;
          -  CF and Non-CF patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of methemoglobinemia or MetHb â‰¥2% at screening; treatment with any drug&#xD;
             known to increase MetHb; known or suspected hemoglobinopathy.&#xD;
&#xD;
          -  History of or current myeloproliferative disease, leukemia or other hematological&#xD;
             malignancy; known or suspected immunodeficiency disease.&#xD;
&#xD;
          -  Subjects with advanced cardiovascular disease or CHF&#xD;
&#xD;
          -  Use of an investigational drug during the 30 days prior to enrollment.&#xD;
&#xD;
          -  History of frequent epistaxis (&gt;1 episode/month); significant hemoptysis (during the&#xD;
             30 days prior to enrollment.&#xD;
&#xD;
          -  Subject on non-constant dose of systemic steroids within 30 days prior to enrollment;&#xD;
             subjects on constant systemic steroids if the daily dose is higher than 10 mg/d&#xD;
             prednisolone or equivalent.&#xD;
&#xD;
          -  Active pulmonary malignancy (primary or metastatic) or any malignancy; history of lung&#xD;
             transplantation.&#xD;
&#xD;
          -  Pulmonary tuberculosis requiring treatment or treated within 2 years prior to&#xD;
             screening.&#xD;
&#xD;
          -  Uncontrolled hypertension within 3 months prior to or at screening&#xD;
&#xD;
          -  Diagnosis of significant pulmonary hypertension indicated on echocardiogram at&#xD;
             screening&#xD;
&#xD;
          -  Clinically significant renal or liver laboratory abnormalities&#xD;
&#xD;
          -  History of daily, continuous oxygen supplementation.&#xD;
&#xD;
          -  Women of childbearing potential - pregnant or breastfeeding, or not on medically&#xD;
             acceptable double methods of contraception from enrollment until Day 84.&#xD;
&#xD;
          -  Smoking tobacco or any substance within 6 months prior to screening or anticipated&#xD;
             inability to refrain from smoking throughout the study.&#xD;
&#xD;
          -  Patient receiving drugs that have a contraindication with NO&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Vladislava Zamfirova</last_name>
    <phone>4102364368</phone>
    <email>vzamfirova@beyondair.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Enoch Bortey</last_name>
    <phone>9198891214</phone>
    <email>ebortey@beyondair.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gallipoli Medical Research Foundation</name>
      <address>
        <city>Greenslopes</city>
        <state>Queensland</state>
        <zip>4120</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Thomson, MD</last_name>
      <email>r.thomson@uq.edu.au</email>
    </contact>
    <investigator>
      <last_name>Rachel Thomson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 7, 2020</study_first_submitted>
  <study_first_submitted_qc>December 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2020</study_first_posted>
  <last_update_submitted>December 24, 2020</last_update_submitted>
  <last_update_submitted_qc>December 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Mycobacterium Infections</mesh_term>
    <mesh_term>Mycobacterium avium-intracellulare Infection</mesh_term>
    <mesh_term>Mycobacterium Infections, Nontuberculous</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

